Abstract
The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Recent Patents on Anti-Cancer Drug Discovery
Title:Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Volume: 10 Issue: 3
Author(s): Douglas R. Abdalla, Cindy Simoens, John-Paul Bogers, Eddie F.C. Murta and Marcia A. Michelin
Affiliation:
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Abstract: The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.
Export Options
About this article
Cite this article as:
Abdalla R. Douglas, Simoens Cindy, Bogers John-Paul, Murta F.C. Eddie and Michelin A. Marcia, Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (3) . https://dx.doi.org/10.2174/1574892810999150827153642
DOI https://dx.doi.org/10.2174/1574892810999150827153642 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hot Melt Extruded and Injection Moulded Dosage Forms: Recent Research and Patents
Recent Patents on Drug Delivery & Formulation Design and Synthesis of 3,4-diarylpyrrole Analogues as Potent Topoisomerase Inhibitors
Medicinal Chemistry Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Herbal Immunomodulators - A Remedial Panacea for Designing and Developing Effective Drugs and Medicines: Current Scenario and Future Prospects
Current Drug Metabolism From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Nutritional Attributes and Health Application of Seabuckthorn (<i>Hippophae rhamnoides</i> L.) – A Review
Current Nutrition & Food Science Carbon Nanoparticles in Mongolian Medicine Alleviate Acute Gastric Ulcer Induced by Ethanol by Regulating Fas/FasL Pathway
Current Drug Delivery Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Performance of PET/CT for Detecting the Primary Tumors of Cervical Metastases from Unknown Primary Carcinoma: A Systematic Review and Meta-Analysis
Current Medical Imaging Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles
Mini-Reviews in Medicinal Chemistry The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Structure, Genome, Infection Cycle and Clinical Manifestations Associated with Human Papillomavirus
Current Pharmaceutical Biotechnology Targeting Tumor Proteasome with Traditional Chinese Medicine
Current Drug Discovery Technologies Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes
Current Molecular Medicine Synthesis of (25R)-17α-Hydroxy-22-oxocholest-5-ene-3β,16β,26-triyl Triacetate: A One-Pot Approach to the Protected Aglycon Analogue of OSW-1
Letters in Organic Chemistry